Increased serum interleukin-33 levels in patients with Graves' disease. 2013

H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
Biochemistry Department, Turgut Ozal University Faculty of Medicine, Ankara, Turkey. htugrulcelik@hotmail.com

OBJECTIVE Interleukin-33 (IL-33), a 30 kDa cytokine, is a member of IL-1 family. It is considered to be an autoimmune biomarker associated with T helper 2 (Th 2) response. γ-interferon is also produced by T helper 1 (Th 1) cells to induce cellular responses. γ-interferon is a 143-amino acid residue glycoprotein with several biological functions including potent anti-viral activity, stimulation of macrophage activity, modulation of Major Histocompatibilty Complex class I/class II expression, and regulation of a diversity of specific immune responses. The aim of this study was to investigate the serum levels of IL-33 and γ-interferon in different thyroid disorders. METHODS Twenty patients with Graves' disease, 21 patients with Hashimoto hypothyroidism, 21 euthyroid Hashimoto patients, and 27 control subjects were recruited to this study. Blood samples were drawn and IL-33 and γ-interferon tests were analyzed from 89 participants. Serum IL-33 and γ-interferon analyses were performed by enzyme-linked immunosorbent assay. RESULTS There was no statistically significant difference between groups for serum γ-interferon levels. Serum IL-33 concentrations were significantly higher in Graves' disease group compared to the other groups (p<0.000) There was a positive correlation between serum IL-33 and free triiodothyronine (fT3) and thyroxine (fT4). Also, negative correlation between serum IL-33 and thyroid-stimulating hormone (TSH) was statistically significant (p<0.000). CONCLUSIONS The correlation of serum IL-33 with thyroid hormone levels may be a useful indicator for Graves' disease. These findings may help to make evident the pathophysiologic processes of the autoimmune thyroid diseases and improve therapeutic methods. .

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067596 Interleukin-33 A member of the INTERLEUKIN-1 protein family involved in the maturation of TH2 CELLS and the activation of MAST CELLS; BASOPHILS; EOSINOPHILS and NK CELLS. It is also produced by ENDOTHELIAL CELLS; EPITHELIAL CELLS and FIBROBLASTS; where it can function as an alarmin to modulate immune and inflammatory responses to tissue damage. IL-33,IL33,Interleukin 33
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
August 1999, European journal of endocrinology,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
September 2000, Thyroid : official journal of the American Thyroid Association,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
May 2014, Journal of the American Academy of Dermatology,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
January 1993, Experimental and clinical endocrinology,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
October 2022, Journal of clinical laboratory analysis,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
January 2015, Journal of the American Academy of Dermatology,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
December 2011, Digestive diseases and sciences,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
December 2018, International journal of rheumatic diseases,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
January 2022, Journal of clinical laboratory analysis,
H T Celik, and S Abusoglu, and S F Burnik, and S Sezer, and M A Serdar, and M Ercan, and N Uguz, and M Avcikucuk, and Bal Ceylan, and M Yildirimkaya
February 1999, Thyroid : official journal of the American Thyroid Association,
Copied contents to your clipboard!